Consider reduction of dialysis work on On-line HDF implementation ~ From timing of drug administration ~
Not Applicable
- Conditions
- Patients in need of treatment for renal anemia due to ESA administration in patients under On-line HDF treatment
- Registration Number
- JPRN-UMIN000026361
- Lead Sponsor
- Kaikoukai Medical Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with anemia due to factors other than renal anemia (2) Patients with hypersensitivity to epoetin beta (genetical recombination), darbepoietin alpha (genetical recombination), epoetin beta pegol (genetical recombination) (3) Patients with malignant tumors (4) Pregnant women or patients who may be pregnant, breastfeeding, or who desire pregnancy during research participation (women only) (5) Other Research Responsibilities (In charge) Patients judged by doctors as inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Administration of 30 (30 each) between the three groups of epoetin beta (genetical recombination) group, darbepoietin alpha (genetical recombination) group and epoetin beta pegol (gene recombination) group was administered on-line from the end of on-line HDF Change the target hemoglobin (Hb) maintenance rate and ESA dose during the HDF execution (1 to 2 hours after the start) to examine whether there is an influence due to the change of the ESA administration timing.
- Secondary Outcome Measures
Name Time Method